25 ALI = acute lung injury; ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; fMLP = formyl-methionyl-leucyl-phenylalanine; IL = interleukin; KGF = keratinocyte growth factor; LPS = lipopolysaccharide; SP = surfactant protein; TNF = tumour necrosis factor. [1]. Morbidity among survivors is also high, with persistent functional limitation 1 year after discharge preventing over half from returning to work [6].Improvements in general supportive care have contributed toward a trend of decreasing mortality over the past 10 years [7], and recently strategies to reduce the effects of ventilatorassociated lung injury have resulted in an important reduction in mortality [8]. However, as yet no specific pharmacological therapies to target the underlying pathological processes have proved efficacious [9]. Recent in vitro and in vivo animal or human studies suggest that β 2 -agonists -drugs that are well established in the management of patients with chronic bronchitis or asthma -may have an important therapeutic role to play in modulating the initial inflammatory insult and enhancing alveolar fluid clearance in patients with ARDS.The present review discusses the effects of β 2 -agonists on neutrophil functions, on inflammatory mediators, and on epithelial and endothelial functions (Fig. 1). It draws on the extensive experimental and clinical literature on the mechanisms of effects of β 2 -agonists to suggest a potential role for their use as a specific pharmacological intervention in patients with ARDS.
ReviewBench-to-bedside review: β β 2 -Agonists and the acute respiratory distress syndrome
AbstractThe acute respiratory distress syndrome (ARDS) is a devastating constellation of clinical, radiological and pathological signs characterized by failure of gas exchange and refractory hypoxia. Despite nearly 30 years of research, no specific pharmacological therapy has yet proven to be efficacious in manipulating the pathophysiological processes that underlie this condition. Several in vitro and in vivo animal or human studies suggest a potential role for β 2 -agonists in the treatment of ARDS. These agents have been shown to reduce pulmonary neutrophil sequestration and activation, accelerate alveolar fluid clearance, enhance surfactant secretion, and modulate the inflammatory and coagulation cascades. They are also used widely in clinical practice and are well tolerated in critically ill patients. The present review examines the evidence supporting a role for β 2 -agonists as a specific pharmacological intervention in patients with ARDS.